Materials and methods to enhance hematopoietic stem cells engraftment procedures
This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE 2 biosynthesis or PGE 2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE 2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE 2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E 2 (dmPGE 2 ), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.
1. A method of enhancing viral transduction efficacy in at least one human hematopoietic stem or progenitor cell, comprising treating the cell ex vivo with an effective amount of a prostaglandin E2 or a derivative thereof; and transducing the cell with a viral vector that contains at least one gene of interest, wherein viral transduction efficacy of the at least one cell is enhanced compared to non-treated human hematopoietic stem or progenitor cell.
2. The method according to claim 1 , wherein the prostaglandin E2 or a derivative thereof is selected from the group consisting of PGE 2 and dmPGE 2 .
3. The method according to claim 1 , wherein said method further comprises the step of administering the cell to a patient.
4. The method according to claim 1 , wherein said hematopoietic stem cell is obtained from Umbilical Cord Blood (UCB) or mobilized Peripheral Blood (PB).
5. A method of enhancing viral transduction efficacy in at least one human hematopoietic stem or progenitor cell comprising:
contacting the at least one cell ex vivo with an effective amount of a prostaglandin E 2 or a derivative thereof and a viral vector that contains at least one gene of interest wherein viral transduction efficacy of the at least one cell is enhanced compared to the human hematopoietic stem or progenitor cell not contacted with a prostaglandin E2 or a derivative thereof.
6. The method according to claim 5 , wherein the prostaglandin E 2 or a derivative thereof is selected from the group consisting of PGE 2 and dmPGE 2 .
7. The method according to claim 5 , wherein the cell is contacted with the prostaglandin E 2 or a derivative thereof for about one to about 6 hours.
8. The method according to claim 5 , wherein the cell is contacted with the prostaglandin E 2 or a derivative thereof for about 2 hours.
9. The method according to claim 5 , wherein the cell is washed after contact with the prostaglandin E 2 or a derivative thereof.
10. The method according to according to claim 5 , wherein the cell is washed prior to being transplanted into a subject.
11. A method of increasing viral transduction efficacy in human hematopoietic stem and progenitor cells comprising:
contacting the cells ex vivo with an effective amount of a prostaglandin E 2 or a derivative thereof and transducing the cells with a viral vector, wherein viral transduction efficacy of the cells is increased compared to non-contacted human hematopoietic stem and progenitor cells.
12. The method according to claim 11 , wherein the cells are contacted with the prostaglandin E 2 or a derivative thereof for at least one hour.
13. The method according to claim 11 , wherein the cells are contacted with the prostaglandin E 2 or a derivative thereof for about one to about 6 hours.
14. The method according to claim 11 , wherein the prostaglandin E 2 or a derivative thereof is selected from the group consisting of PGE 2 and dmPGE 2 .
15. The method according to claim 11 , wherein the human hematopoietic stem cells are Lineage negative (Lin Neg ) cells.
16. The method according to claim 11 , wherein the human hematopoietic stem cells are CD34+ cells.